. Author manuscript; available in PMC: 2018 Nov 1.

Published in final edited form as: Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Jan 21;2(8):696–705. doi: 10.1016/j.bpsc.2016.12.008

Table 2.

Additional Characteristics of CHR Participants

Characteristics	CHR Participants (n=51)
SIPS Score
Total Positive Symptoms	12.33 (SD 4.58)
Total Negative Symptoms	14.98 (SD 7.73)
CHR Outcome
Converted to Psychosis, n (%)	12/51 (23.5%)
Mean Time to Conversion, months	17.05 ± 7.5
Baseline GSF:R^*, n=45	5.86 (SD=2.2)
Last GFS:R^**, n=39	6.28 (SD=1.65)
Baseline GSF:S^*, n=45	5.9 (SD=1.4)
Last GFS:S^**, n=40	5.72 (SD=3.00)
Poor Outcome: GFS: ≤ 6, n (%)	19/39 (48.72%)
Poor Outcome: GFS:S ≤ 6, n (%)	19/40 (47.5%)
Medication Type^***, n
Atypical/Typical Antipsychotics	8/0
Mood Stabilizers	1
Antidepressants	17
Stimulants	5
Benzodiazepines	5

Indicates incomplete data;

^**

The mean Follow-Up Period (Time to Last Follow Up) was 17.37 months (n=51; SD= 15.0).

^***

Information about medication was unavailable for 5 participants